Curaleaf Holdings (CURLF) Non Operating Income (2019 - 2026)

Curaleaf Holdings (CURLF) posted quarterly Non Operating Income of -$29.4 million for Q1 2026, down 14.03% year-on-year from -$34.2 million in Q1 2025, and down 8.61% on a QoQ basis from -$27.1 million in Q4 2025.

Curaleaf Holdings (CURLF) Non Operating Income (2019 - 2026) Analysis & Trends

Curaleaf Holdings (CURLF) has reported Non Operating Income for 8 consecutive years, with -$29.4 million the latest figure, recorded in Q1 2026.

  • Quarterly Non Operating Income fell 14.03% year-over-year to -$29.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$107.3 million (up 23.21% YoY) and the FY2025 annual result came in at -$103.7 million, up 24.94% from the prior year.
  • Non Operating Income eased to -$29.4 million in Q1 2026 per CURLF's latest filing, from -$27.1 million in the prior quarter.
  • Over the last five years, Non Operating Income for CURLF reached as high as -$3.2 million in Q2 2022 and fell as low as -$74.6 billion in Q4 2023.
  • A 5-year average of -$4.4 billion and a median of -$24.7 million in 2024 frame the typical range for Non Operating Income.
  • Annual changes were most pronounced in 2023 — Non Operating Income sank 44383.47% — and 2024, when it jumped 99.91%.
  • Year by year, Non Operating Income stood at -$167.7 million in 2022, then plunged by 44383.47% to -$74.6 billion in 2023, then soared by 99.91% to -$68.2 million in 2024, then soared by 60.35% to -$27.1 million in 2025, then slipped by 8.61% to -$29.4 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods registered -$29.4 million, -$27.1 million, and -$28.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -216.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 20.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -7.50 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 53.40 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Curaleaf Holdings 7.13 Bn 7.13 Bn 157.29 Mn -29.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -29.38 Mn
Dec 31, 2025 -27.05 Mn
Sep 30, 2025 -28.34 Mn
Jun 30, 2025 -22.51 Mn
Mar 31, 2025 -25.77 Mn
Dec 31, 2024 -68.23 Mn
Sep 30, 2024 -21.01 Mn
Jun 30, 2024 -24.71 Mn
Mar 31, 2024 -24.19 Mn
Dec 31, 2023 -74.59 Bn
Sep 30, 2023 -51.17 Mn
Jun 30, 2023 -20.36 Mn
Mar 31, 2023 -21.13 Mn
Dec 31, 2022 -167.69 Mn
Sep 30, 2022 -23.97 Mn
Jun 30, 2022 -3.20 Mn
Mar 31, 2022 -22.35 Mn
Dec 31, 2021 -50.86 Mn
Sep 30, 2021 -38.96 Mn
Jun 30, 2021 -19.03 Mn